SCHEMBL1011104

SCHEMBL1011104

CCC(Oc1cccc(C=O)c1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.55
PPARG P37231 5/20 0.48
PPARA Q07869 5/20 0.48
MAOA P21397 4/20 0.48
MAOB P27338 4/20 0.48
SRC P12931 1/20 0.46
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
UNG P13051 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
POLB P06746 1/20 0.43
FABP4 P15090 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.42
FOLH1 Q04609 1/20 0.42
GRIK1 P39086 1/20 0.41
GRIK2 Q13002 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2174551 1.00 SMN1; SMN2 (0.55) SMN1; SMN2PPARGPPARAMAOAMAOB
SCHEMBL2552246 0.87 SRC (0.45) SMN1; SMN2MAOAMAOBSRCALDH1A1
SCHEMBL1011005 0.85 AR (0.50) SMN1; SMN2MAOAMAOBSRCALDH1A1
SCHEMBL1949996 0.85 NPC1 (0.45) SMN1; SMN2MAOAMAOBSRCALDH1A1
SCHEMBL3066415 0.84 MAOA (0.44) SMN1; SMN2PPARGPPARAMAOAMAOB
SCHEMBL997736 0.83 SMN1; SMN2 (0.59) SMN1; SMN2PPARGPPARAALDH1A1
SCHEMBL1008004 0.82 SRC (0.41) SMN1; SMN2MAOAMAOBSRCALDH1A1
SCHEMBL13864205 0.81 TLR4 (0.42) SMN1; SMN2PPARGPPARAMAOAMAOB
SCHEMBL4651839 0.80 SMN1; SMN2 (0.64) SMN1; SMN2PPARGPPARAALDH1A1
SCHEMBL295888 0.80 SMN1; SMN2 (0.64) SMN1; SMN2PPARGPPARAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 WO disclosed
US-20110046385-A1 Polymorphs Of Prostaglandin Agonists And Methods For Making The Same PFIZER PRODUCTS INC. (US) 2011-02-24 US disclosed
EP-1661890-B1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KOWA CO (JP) 2011-01-05 EP disclosed
EP-2185516-A2 POLYMORPHS OF 3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL)-PHENOXY)-ACETIC ACID SODIUM SALT OR A HYDRATE THEREOF AND METHODS FOR MAKING THE SAME Pfizer Products Incorporated (US) 2010-05-19 EP disclosed
US-7538242-B2 Optically active PPAR-activating compound intermediate and method for producing same KOWA CO., LTD. (JP) 2009-05-26 US disclosed
WO-2009027811-A2 POLYMORPHS OF 3- ( ( (4-TERT-BUTYL-BENZYL) - (PYRIDINE-3-SULFONYL) -AMINO) -METHYL) -PHENOXY) -ACETIC ACID SODIUM SALT OR A HYDRATE THEREOF AND METHODS FOR MAKING THE SAME PFIZER PRODUCTS INC. (US) 2009-03-05 WO disclosed
WO-2009027803-A2 POLYMORPHS OF (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL)- PHENOXY)-ACETIC ACID, FREE ACID PFIZER PRODUCTS INC. (US) 2009-03-05 WO disclosed
US-20090023944-A1 OPTICALLY ACTIVE PPAR-ACTIVATING COMPOUND INTERMEDIATE AND METHOD FOR PRODUCING SAME KOWA CO., LTD. (JP) 2009-01-22 US disclosed
WO-2008152388-A1 SILICON-CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF BONE LOSS OR RESTORATION OF BONE MASS, OR AUGMENTATION OF BONE MASS OPAL DRUG DISCOVERY LIMITED (GB) 2008-12-18 WO disclosed
EP-1854779-A1 OPTICALLY ACTIVE PPAR-ACTIVATING COMPOUND INTERMEDIATE AND METHOD FOR PRODUCING SAME Kowa Company, Ltd. (JP) 2007-11-14 EP disclosed
US-7183295-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2007-02-27 US disclosed
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-08-24 US disclosed
EP-1661890-A1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Kowa Co., Ltd. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046385-A1 Polymorphs Of Prostaglandin Agonists And Methods For Making The Same PTGER1, PTGER3, PTGER4 SMN1; SMN2 4729/4885PPARG 19/4885PPARA 26/4885
US-20090023944-A1 OPTICALLY ACTIVE PPAR-ACTIVATING COMPOUND INTERMEDIATE AND METHOD FOR PRODUCING SAME PPARA, PPARG, PPARD SMN1; SMN2 4832/4885PPARG 2/4885PPARA 1/4885
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARA, PPARG, PPARD SMN1; SMN2 4340/4885PPARG 2/4885PPARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.